MedTrace Logo

Masitinib in Treatment of Patients With Severe Persistent Asthma Treated With Oral Corticosteroids

NCT01449162 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 420

Last updated 2021-02-10

No results posted yet for this study

Summary

The study objective is to compare the efficacy and the safety of masitinib at 6 mg/kg/day versus placebo in the treatment of patients with Severe Persistent Asthma treated with oral corticosteroids.

Conditions

Interventions

DRUG

Masitinib

6 mg/kg/day

DRUG

Placebo

Sponsors & Collaborators

  • AB Science

    lead INDUSTRY

Principal Investigators

  • Lavinia Davidescu, MD, PhD · University of Medicine and Pharmacy Oradea, Oradea, Romania

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2019-11-30
Completion
2019-11-30

Countries

  • Bulgaria
  • Czechia
  • France
  • Hungary
  • India
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01449162 on ClinicalTrials.gov